Clarity Pharmaceuticals Ltd (ASX:CU6) secured a fast-track designation from the US Food and Drug Administration for the prostate cancer imaging agent 64Cu-SAR-bisPSMA, according to a Friday filing with the Australian bourse.
The designation will allow for an expedited regulatory review of the product, the filing said.
Company shares rose past 4% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.